FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281609929> ?p ?o ?g. }

• W4281609929 abstract "Abstract Background Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK/PD, and evaluate the safety and efficacy of FGF401 alone and combined with the anti-PD-1 antibody, spartalizumab. Methods Patients with HCC or other FGFR4/KLB expressing tumors were enrolled. Dose-escalation was guided by a Bayesian model. Phase 2 dose-expansion enrolled patients with HCC from Asian countries (group1), non-Asian countries (group2), and patients with other solid tumors expressing FGFR4 and KLB (group3). FGF401 and spartalizumab combination was evaluated in patients with HCC. Results Seventy-four patients were treated in the phase I with single-agent FGF401 at 50 to 150 mg. FGF401 displayed favorable PK characteristics and no food effect when dosed with low-fat meals. The RP2D was established as 120 mg qd. Six of 70 patients experienced grade 3 dose-limiting toxicities: increase in transaminases ( n = 4) or blood bilirubin ( n = 2). In phase 2, 30 patients in group 1, 36 in group 2, and 20 in group 3 received FGF401. In total, 8 patients experienced objective responses (1 CR, 7 PR; 4 each in phase I and phase II, respectively). Frequent adverse events (AEs) were diarrhea (73.8%), increased AST (47.5%), and ALT (43.8%). Increase in levels of C4, total bile acid, and circulating FGF19, confirmed effective FGFR4 inhibition. Twelve patients received FGF401 plus spartalizumab. RP2D was established as FGF401 120 mg qd and spartalizumab 300 mg Q3W; 2 patients reported PR. Conclusions At biologically active doses, FGF401 alone or combined with spartalizumab was safe in patients with FGFR4/KLB-positive tumors including HCC. Preliminary clinical efficacy was observed. Further clinical evaluation of FGF401 using a refined biomarker strategy is warranted. Trial registration NCT02325739 ." @default.
• W4281609929 created "2022-06-12" @default.
• W4281609929 creator A5001201465 @default.
• W4281609929 creator A5002687748 @default.
• W4281609929 creator A5005925636 @default.
• W4281609929 creator A5006079441 @default.
• W4281609929 creator A5008933620 @default.
• W4281609929 creator A5015598872 @default.
• W4281609929 creator A5017400559 @default.
• W4281609929 creator A5023048065 @default.
• W4281609929 creator A5026725352 @default.
• W4281609929 creator A5028020706 @default.
• W4281609929 creator A5028950420 @default.
• W4281609929 creator A5032900701 @default.
• W4281609929 creator A5036507802 @default.
• W4281609929 creator A5039119608 @default.
• W4281609929 creator A5040030135 @default.
• W4281609929 creator A5046201209 @default.
• W4281609929 creator A5046498356 @default.
• W4281609929 creator A5050470043 @default.
• W4281609929 creator A5050960262 @default.
• W4281609929 creator A5055498702 @default.
• W4281609929 creator A5066646841 @default.
• W4281609929 creator A5069185084 @default.
• W4281609929 creator A5069522018 @default.
• W4281609929 creator A5071276908 @default.
• W4281609929 creator A5073989429 @default.
• W4281609929 creator A5076696174 @default.
• W4281609929 creator A5079645039 @default.
• W4281609929 creator A5080019152 @default.
• W4281609929 creator A5081604639 @default.
• W4281609929 creator A5082191671 @default.
• W4281609929 creator A5082631947 @default.
• W4281609929 creator A5083417161 @default.
• W4281609929 creator A5083760620 @default.
• W4281609929 creator A5084349853 @default.
• W4281609929 creator A5088566246 @default.
• W4281609929 creator A5090048812 @default.
• W4281609929 date "2022-06-02" @default.
• W4281609929 modified "2023-10-17" @default.
• W4281609929 title "A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors" @default.
• W4281609929 cites W1539520316 @default.
• W4281609929 cites W1960850967 @default.
• W4281609929 cites W1971837077 @default.
• W4281609929 cites W1994193851 @default.
• W4281609929 cites W2078058991 @default.
• W4281609929 cites W2095943598 @default.
• W4281609929 cites W2114104545 @default.
• W4281609929 cites W2130787560 @default.
• W4281609929 cites W2134526812 @default.
• W4281609929 cites W2159707944 @default.
• W4281609929 cites W2169456326 @default.
• W4281609929 cites W2171668245 @default.
• W4281609929 cites W2277004004 @default.
• W4281609929 cites W2606367731 @default.
• W4281609929 cites W2773998260 @default.
• W4281609929 cites W2787358630 @default.
• W4281609929 cites W2800499107 @default.
• W4281609929 cites W2803626382 @default.
• W4281609929 cites W2805592007 @default.
• W4281609929 cites W2889646458 @default.
• W4281609929 cites W2898464548 @default.
• W4281609929 cites W2898830231 @default.
• W4281609929 cites W2929062492 @default.
• W4281609929 cites W2941542116 @default.
• W4281609929 cites W2947802634 @default.
• W4281609929 cites W2948685669 @default.
• W4281609929 cites W2968913253 @default.
• W4281609929 cites W2969583426 @default.
• W4281609929 cites W2977600124 @default.
• W4281609929 cites W3011361209 @default.
• W4281609929 cites W3025022288 @default.
• W4281609929 cites W3045387409 @default.
• W4281609929 cites W3087582521 @default.
• W4281609929 cites W3119451450 @default.
• W4281609929 cites W3152534107 @default.
• W4281609929 cites W3155194275 @default.
• W4281609929 cites W3165017392 @default.
• W4281609929 cites W3166337570 @default.
• W4281609929 cites W3213277274 @default.
• W4281609929 cites W3216779670 @default.
• W4281609929 cites W4205565447 @default.
• W4281609929 cites W4232620598 @default.
• W4281609929 doi "https://doi.org/10.1186/s13046-022-02383-5" @default.
• W4281609929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35655320" @default.
• W4281609929 hasPublicationYear "2022" @default.
• W4281609929 type Work @default.
• W4281609929 citedByCount "11" @default.
• W4281609929 countsByYear W42816099292022 @default.
• W4281609929 countsByYear W42816099292023 @default.
• W4281609929 crossrefType "journal-article" @default.
• W4281609929 hasAuthorship W4281609929A5001201465 @default.
• W4281609929 hasAuthorship W4281609929A5002687748 @default.
• W4281609929 hasAuthorship W4281609929A5005925636 @default.
• W4281609929 hasAuthorship W4281609929A5006079441 @default.
• W4281609929 hasAuthorship W4281609929A5008933620 @default.
• W4281609929 hasAuthorship W4281609929A5015598872 @default.
• W4281609929 hasAuthorship W4281609929A5017400559 @default.
• W4281609929 hasAuthorship W4281609929A5023048065 @default.
• W4281609929 hasAuthorship W4281609929A5026725352 @default.

• next